Korea Bone Bank Co

Seoul, South Korea

Korea Bone Bank Co

Seoul, South Korea
SEARCH FILTERS
Time filter
Source Type

Cho E.-S.,Chonbuk National University | Kim M.-K.,Chonbuk National University | Son Y.-O.,University of Kentucky | Lee K.-S.,Korea Bone Bank Co. | And 3 more authors.
Molecules and Cells | Year: 2012

Rosiglitazone has the potential to activate peroxisome proliferator- activated receptor-γ (PPARγ), which in turn can affect bone formation and resorption. However, the mechanisms by which rosiglitazone regulates osteoclastic or osteoblastic differentiation are not fully understood. This study examines how rosiglitazone affects osteoclast formation, bone resorption and osteoblast differentiation from mouse bone marrow. Rosiglitazone treatment not only inhibited the formation of tartrate-resistant acid phosphatase-positive cells, but also prevented pit formation by bone marrow cells in a dose- and time-dependent manner. Rosiglitazone also suppressed the receptor activator of nuclear factor (NF)-κB ligand (RANKL) receptor (RANK) expression but increased PPARγ2 expression in the cells. In addition, rosiglitazone diminished RANKL-induced activation of NF-κB-DNA binding by blocking IκBα phosphorylation. Furthermore, it reduced collagen and osteocalcin levels to nearly zero and prevented mRNA expression of osteoblast-specific proteins including runtrelated transcription factor-2, osteocalcin, and type I collagen. However, mRNA levels of adipocyte-specific marker, aP2, were markedly increased in the cells co-incubated with rosiglitazone. These results suggest that PPARγ activation by rosiglitazone inhibits osteoblast differentiation with increased adipogenesis in bone marrow cells and also may prevent osteoclast formation and bone resorption in the cells. © 2012 KSMCB.


Jang J.-W.,Yonsei University | Yun J.-H.,Inha University | Lee K.-I.,Korea Bone Bank Co | Jang J.-W.,Korea Bone Bank Co | And 4 more authors.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology | Year: 2012

Objective. The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2. Study Design. Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks. Results. The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP. Conclusions. rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study. © 2012 Elsevier Inc. All rights reserved.


Kim J.-W.,Yonsei University | Jeong I.-H.,Inha University | Lee K.-I.,Korea Bone Bank Co. | Jung U.-W.,Yonsei University | And 4 more authors.
Journal of Biomedical Materials Research - Part A | Year: 2012

Block-type biphasic calcium phosphate (BCP) carriers are more effective at delivering recombinant human bone morphogenetic protein-2 (rhBMP-2) in various clinical situations than are particle-type carriers, due to their potential for highly successful three-dimensional bone regeneration. The aim of this study was to confirm the boneregenerative capabilities of three-dimensional BCP blocks with a low hydroxyapatite/β-tricalcium phosphate ratio (20/80) combined with collagen (10% wt) as an rhBMP-2 delivery system in a craniofacial vertical bone augmentation model. BCP blocks and BCP-collagen blocks (with average macropore sizes of 296 and 390 μm, respectively) with or without rhBMP-2 were fixed with osteosynthesis screws to the calvarial surface of rabbits. After 8 weeks, histologic and histomorphometric analyses were performed to evaluate the resulting new bone area, augmented area, bone density, and degree of integration. The area of new bone was significantly greater in specimens containing rhBMP-2 than in the control group (p< 0.05). Moreover, the area fractions of newly formed bone within the augmented area and a degree of integration between the regenerative bone and the calvarium were both significantly greater in the BCP-collagen/rhBMP-2 group than in the BCP/rhBMP-2 group (p< 0.05), whereas the two carrier systems exhibited similar rhBMP-2 release profiles, with sustained and linear release. The BCP and BCP/rhBMP-2 blocks exhibited excellent structural integrity, with large fragments of residual ceramic. In conclusion, the BCP-collagen composite block exhibited enhanced osteoinductive potential and could be a good candidate as a carrier of rhBMP-2 due to its characteristics of favorable volumetric stability, ease of handling, and excellent remodeling properties. © 2012 Wiley Periodicals, Inc.


Kim S.J.,Catholic University of Korea | Yang D.H.,Catholic University of Korea | Chun H.J.,Catholic University of Korea | Chae G.T.,Catholic University of Korea | And 2 more authors.
Macromolecular Research | Year: 2013

The objective of the present study was to evaluate non-woven chitosan/poly(lactic-co-glycolic acid) fibrous scaffold (chitosan/PLGA FS) prepared by a co-electrospinning process for tissue engineering applications, as compared to chitosan and PLGA FSs. The morphological, structural, and mechanical properties of the FSs were assessed by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy-attenuated total reflection mode (FTIR-ATR), and a universal testing machine (UTM). The biocompatibility of the FSs was also evaluated in vitro in cultures of mouse fibroblasts and in vivo by subcutaneous implantation studies in rats. SEM image of the chitosan/PLGA FS showed morphological similarities to the natural ECM, characterized by high surface-to-volume ratio, high porosity, and variable pore size distributions. The FTIR-ATR spectrum of chitosan/PLGA FS revealed incorporation of the characteristic bands of chitosan and PLGA, indicating the co-existence of two fibrous structures. The poor mechanical properties of chitosan FS was improved by co-electrospinning with PLGA. In vitro L929 cell proliferation assay revealed that the cytocompatibility of chitosan/PLGA FS was increased compared to that of PLGA. In addition, chitosan/PLGA FS showed the improved ability to resolve foreign body reactions compared to PLGA FS due to the presence of chitosan. © 2013 The Polymer Society of Korea and Springer Sciene+Business Media Dordrecht.


Lee S.-Y.,Chonbuk National University | Lee K.-S.,Chonbuk National University | Lee K.-S.,Korea Bone Bank Co. | Yi S.H.,Chonbuk National University | And 2 more authors.
PLoS ONE | Year: 2013

Numerous studies have reported that inflammatory cytokines are important mediators for osteoclastogenesis, thereby causing excessive bone resorption and osteoporosis. Acteoside, the main active compound of Rehmannia glutinosa, which is used widely in traditional Oriental medicine, has anti-inflammatory and antioxidant potentials. In this study, we found that acteoside markedly inhibited osteoclast differentiation and formation from bone marrow macrophages (BMMs) and RAW264.7 macrophages stimulated by the receptor activator of nuclear factor-kappaB (NF-κB) ligand (RANKL). Acteoside pretreatment also prevented bone resorption by mature osteoclasts in a dose-dependent manner. Acteoside (10 μM) attenuated RANKL-stimulated activation of p38 kinase, extracellular signal-regulated kinases, and c-Jun N-terminal kinase, and also suppressed NF-κB activation by inhibiting phosphorylation of the p65 subunit and the inhibitor κBα. In addition, RANKL-mediated increases in the expression of c-Fos and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) and in the production of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 were apparently inhibited by acteoside pretreatment. Further, oral acteoside reduced ovariectomy-induced bone loss and inflammatory cytokine production to control levels. Our data suggest that acteoside inhibits osteoclast differentiation and maturation from osteoclastic precursors by suppressing RANKL-induced activation of mitogen-activated protein kinases and transcription factors such as NF-κB, c-Fos, and NFATc1. Collectively, these results suggest that acteoside may act as an anti-resorptive agent to reduce bone loss by blocking osteoclast activation. © 2013 Lee et al.


Patent
Korea Bone Bank Co. | Date: 2010-05-10

The present invention relates to a process for forming a porous poly(vinyl alcohol) (PVA) scaffold using a pore-forming agent, and more particularly, to a process for forming a porous PVA scaffold using a pore-forming agent, comprising: mixing PVA with the pore-forming agent to form micropores in the PVA scaffold and using an easily decomposable pore-forming agent after the formation of the pores to improve convenience and reduce the processing time in manufacturing the porous PVA scaffold as well as to enable a pore size and porosity to be selected. A process for forming a porous PVA scaffold using a pore-forming agent according to the present invention includes heating to melt the PVA, cooling the melted PVA and mixing the PVA with a heat-decomposable pore-forming agent, repeating the freezing/thawing of the mixed PVA to cure the PVA mixture, and stirring the cured PVA mixture with a hydrochloric acid solution at a high temperature of 65 C. or more to produce foam.


Patent
Korea Bone Bank Co. | Date: 2012-05-23

The present invention relates to a process for forming a porous poly(vinyl alcohol) (PVA) scaffold using a pore-forming agent, and more particularly, to a process for forming a porous PVA scaffold using a pore-forming agent, comprising: mixing PVA with the pore-forming agent to form micropores in the PVA scaffold and using an easily decomposable pore-forming agent after the formation of the pores to improve convenience and reduce the processing time in manufacturing the porous PVA scaffold as well as to enable a pore size and porosity to be selected. A process for forming a porous PVA scaffold using a pore-forming agent according to the present invention includes heating to melt the PVA, cooling the melted PVA and mixing the PVA with a heat-decomposable pore-forming agent, repeating the freezing/thawing of the mixed PVA to cure the PVA mixture, and stirring the cured PVA mixture with a hydrochloric acid solution at a high temperature of 65C or more to produce foam.


Patent
Korea Bone Bank Co. | Date: 2010-05-12

The present invention relates to a method for purifying a protein belonging to the TGF-, superfamily, preferably BMP, and more preferably BMP-2. According to the invention, the number of purification steps is reduced and the purification process is simplified, compared to the conventional BMP-2 purification method. Thus, the time required for purification can be shortened and the cost can be reduced. In addition, the invention solves the problem that as the time for purification increases and the number of purification steps increases, BMP-2 is degraded by protease or lost during purification steps, resulting in a decrease in the final yield of BMP-2. Thus, the invention increases the final yield of BMP-2. In addition, according to the invention, although the number of purification steps is reduced, BMP-2 having high purity is obtained in high yield by optimizing and using filtrations and chromatographies, and columns, types and concentrations of buffers, and a cut-off size of membrane used in diafiltration, which are different from those of the conventional BMP-2 purification method.


Patent
Korea Bone Bank Co. | Date: 2012-01-18

The present invention relates to a method for purifying a protein belonging to the TGF- superfamily, preferably BMP, and more preferably BMP-2. According to the invention, the number of purification steps is reduced and the purification process is simplified, compared to the conventional BMP-2 purification method. Thus, the time required for purification can be shortened and the cost can be reduced. In addition, the invention solves the problem that as the time for purification increases and the number of purification steps increases, BMP-2 is degraded by protease or lost during purification steps, resulting in a decrease in the final yield of BMP-2. Thus, the invention increases the final yield of BMP-2. In addition, according to the invention, although the number of purification steps is reduced, BMP-2 having high purity is obtained in high yield by optimizing and using filtrations and chromatographies, and columns, types and concentrations of buffers, and a cut-off size of membrane used in diafiltration, which are different from those of the conventional BMP-2 purification method.


Eos

Trademark
Korea Bone Bank Co. | Date: 2010-10-05

Substitutes for bones, cartilage, ligaments and tendons; osseous implants, artificial bone parts to be implanted in natural bones, surgical implants comprising artificial materials; bone substitutes for surgical use, artificial skin for surgical purposes, artificial bones for implantation, subcutaneous valves for implantation, artificial joints, artificial cartilage, artificial ligaments, artificial jaws.

Loading Korea Bone Bank Co collaborators
Loading Korea Bone Bank Co collaborators